Results 31 to 40 of about 122,145 (339)

Reframing the role of glucagon‐like peptide 1 receptor agonists in cardiovascular medicine

ESC Heart Failure
ESC Heart Failure, Volume 12, Issue 2, Page 923-926, April 2025.
Riccardo M. Inciardi, Alvin Chandra, Ambarish Pandey, Marco Metra   +3 more
doaj   +2 more sources

The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]

, 2013
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core   +2 more sources

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents

Neural Regeneration Research, 2019
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 receptor agonists is a breakthrough in the field of neural regeneration research increasing glucagon like peptide-1 bioavailability, hence its neuroprotective activities.
Shaker A Mousa, Bassam M Ayoub
doaj   +1 more source

Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK

BMJ Open Diabetes Research & Care, 2022
Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a type 2 diabetes mellitus (T2DM) treatment with demonstrated weight loss benefits in clinical trials.
Tracey Weiss, Lingfeng Yang, R. Carr, Sampriti Pal, B. Sawhney, R. Boggs, S. Rajpathak, K. Iglay   +7 more
semanticscholar   +1 more source

Treatment of type 2 diabetes by free fatty acid receptor agonists [PDF]

, 2014
Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors.
Hudson, Brian D., Milligan, Graeme, Ulven, Trond, Watterson, Kenneth R.   +3 more
core   +2 more sources

Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study [PDF]

, 2015
AIMS:Glucagon-like peptide 1 receptor agonists (GLP-1 RA) induce weight loss and reduction in adipose tissue, but the effects of GLP-1 RA on the distribution of fat deposits have been poorly investigated. METHODS: In 25 patients with type 2 diabetes (16
Carnevale, Vincenzo, Dagostino, Mariangela Pia, Fallarino, Mara, Filardi, Tiziana, Lenzi, Andrea, Mandosi, Elisabetta, Morano, Susanna, Nieddu, Luciano, Romagnoli, Elisabetta, Turinese, Irene   +9 more
core   +1 more source

Nephroprotective potential of glucagon-like peptide-1 receptor agonists

Сахарный диабет, 2020
Patients with diabetes mellitus (DM), which is a key factor in the development of kidney diseases, are increasingly competing for limited healthcare resources.
Minara S. Shamkhalova, Igor A. Sklyanik, Marina V. Shestakova   +2 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

Metabolites, 2021
To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we performed a systematic review and meta-analysis of randomized controlled trials (RCTs).
A. Mantovani, Graziana Petracca, Giorgia Beatrice, A. Csermely, A. Lonardo, G. Targher   +5 more
semanticscholar   +1 more source

G-protein-coupled receptors for free fatty acids: nutritional and therapeutic targets [PDF]

, 2014
It is becoming evident that nutrients and metabolic intermediates derived from such nutrients regulate cellular function by activating a number of cell-surface G-protein coupled receptors (GPCRs).
Brian D. Hudson, Graeme Milligan, Hannah Murdoch, Hoveyda, Ma, Saniere, Trond Ulven   +6 more
core   +2 more sources

Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus [PDF]

, 2017
Type 2 diabetes mellitus (T2DM) is associated with skeletal complications, including an increased risk of fractures. Reduced blood supply and bone strength may contribute to this skeletal fragility.
Andreozzi, Anetzberger, Anichini, Aoyama, Baggio, Balint, Ban, Beckman, Bouxsein, Brunton, Chen, Coleman, Dempster, Ealey, Eckel, Feng, Flatt, Friedman, Griffith, Griffith, Hamilton, Hu, Karim, Kim, Lee, Lu, Ma, Mabilleau, Mabilleau, Mansur, Marenzana, Mieczkowska, Napoli, Nuche-Berenguer, Nuche-Berenguer, Nuche-Berenguer, Nystrom, Nystrom, Odgaard, Okerson, Orland, Orriss, Paschalis, Pereira, Pereira, Prisby, Richard, Roche, Roszer, Schalkwijk, Scheller, Selley, Shymkiw, Smits, Stabley, Sun, Tartaglia, Upadhyay, van Bloemendaal, Vijan, Williams, Wu, Yamamoto, Yamamoto, Yamamoto   +64 more
core   +6 more sources